Radiation and immunotherapy combo for DLL3-positive cancers
Treatments studied
Part of Brain & nervous system, Cancer, Hormones & metabolism, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed cancer that makes DLL3, such as small cell lung cancer or certain other tumor types.
- Your cancer must have come back or not responded to at least one prior treatment.
- You must have at least one tumor that can be safely treated with radiation and has not been radiated before.
- You must be able to provide a sample of your tumor from a prior biopsy or agree to a new biopsy.
- You must be in reasonably good health (ECOG 0-2) with a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.